ADXN — Addex Therapeutics Share News
0.000.00%
Last trade - 00:00- CH₣5.17m
- CH₣3.56m
- CH₣0.17m
Brief: Addex H1 Net Loss At CHF 7.3 Million
Brief: Addex Therapeutics And Indivior Extend Research Collaboration On Gabab Positive Allosteric Modulators
Brief: Addex Establishes At-The-Market ADS Equity Sale Program
Brief: Addex Therapeutics Starts Phase 2B/3 Study With Dipraglurant For Dyskinesia
Brief: Addex Starts Phase 2 Clinical Study Of ADX71149 For Epilepsy
Brief: Addex Says Dipraglurant Restores Synaptic Plasticity In Two Models Of Dystonia
Brief: Addex Therapeutics Q1 Net Loss At CHF -2.6 Million
Swiss stocks - Factors to watch on April 8
Brief: Addex Therapeutics Files For Stock Shelf Of Up To $150 Mln
Brief: Addex Therapeutics FY Net Loss narrows to CHF 12.9 Mln
Brief: Addex Therapeutics Extends Collaboration With Prominent Swiss Biotech
Brief: Addex Therapeutics Completes 2020 With Cash Position Of CHF 18.7 Mln
U.S. STOCKS ON THE MOVE-U.S.-listed miners, Exxon Mobil, Blackberry, Palantir
Addex Therapeutics: Rises as alcohol disorder drug promising in review
Brief: Addex Gabab Positive Allosteric Modulator Demonstrates Promise In Alcohol Use Disorder
Addex: Surges as partner Janssen gets FDA nod for epilepsy treatment study
Swiss stocks - Factors to watch on January 21
Brief: Addex: ADX71149 Receives IND Approval To Start Phase 2a Clinical Study In Epilepsy
Brief: Addex Therapeutics Completes Capital Increase